Growth Metrics

Bristol Myers Squibb (BMYMP) Non-Current Deferred Tax Liability (2018 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Non-Current Deferred Tax Liability for 14 consecutive years, with $3.8 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 920.87% to $3.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 billion through Dec 2025, up 920.87% year-over-year, with the annual reading at $3.8 billion for FY2025, 920.87% up from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $3.8 billion at Bristol Myers Squibb, up from $225.0 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $5.2 billion in Q1 2021, with the low at $225.0 million in Q3 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $2.2 billion, with a median of $1.2 billion recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability crashed 93.2% in 2023, then surged 920.87% in 2025.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $4.5 billion in 2021, then grew by 10.35% to $5.0 billion in 2022, then plummeted by 93.2% to $338.0 million in 2023, then grew by 9.17% to $369.0 million in 2024, then soared by 920.87% to $3.8 billion in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $3.8 billion, $225.0 million, and $247.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.